Retatrutide vs. Ozempic: what Lilly’s new trial results actually show

Image disclosure: The image above is an AI-generated conceptual editorial illustration of glass spheres and a research notebook. It is not a photograph of retatrutide, a clinical trial or actual study data.

News reviewed: October 28, 2026. This explainer draws on ABC News reporting, Lilly’s trial announcement and FDA guidance. It is educational reporting, not individualized medical advice.

A headline about an experimental medicine delivering “double the weight loss of Ozempic” deserves a closer look. On October 28, ABC News reported new results for retatrutide, Eli Lilly’s investigational once-weekly injection. The company’s announcement describes a direct comparison with Ozempic 2 mg in adults with type 2 diabetes.

The findings are promising, but their scope matters: they are company-reported topline results from a particular trial, not FDA approval, a guaranteed personal outcome or evidence that a wellness strip produces the same effect.

The news in brief

• What was studied: Retatrutide 9 mg and 12 mg versus injectable Ozempic 2 mg in TRANSCEND-T2D-2, a phase 3 head-to-head trial.
• Who participated: Adults with type 2 diabetes; ABC News reports more than 1,000 participants.
• When results were assessed: At 80 weeks.
• Average weight loss reported: 44.3 pounds and 47.4 pounds with the two retatrutide doses, versus 20.9 pounds with Ozempic.
• Approval status: Retatrutide remains investigational. ABC News reports that Lilly plans an FDA submission in early 2027; a planned submission is not approval.

What the trial results show

According to Lilly’s October 28 announcement, both retatrutide doses produced greater reductions in A1C, a measure of average blood glucose, and greater average weight loss than Ozempic 2 mg at 80 weeks.

• Retatrutide 9 mg: Average weight reduction of 19.5%, or 44.3 pounds.
• Retatrutide 12 mg: Average weight reduction of 20.9%, or 47.4 pounds.
• Ozempic 2 mg: Average weight reduction of 9.4%, or 20.9 pounds.

The average starting body weight was 225.8 pounds, and average starting A1C was 8.3%. A1C fell by 2.2 percentage points with either retatrutide dose, compared with 1.8 percentage points with Ozempic.

These figures come from what Lilly calls the efficacy estimand: a defined approach to estimating the treatment effect. They should be read alongside the full trial methods when published, including how treatment discontinuation and missing measurements were handled. Trial averages do not predict how much weight any individual will lose.

What “double the weight loss” does—and does not—mean

The headline reflects a real head-to-head comparison reported by the manufacturer, rather than a comparison stitched together from unrelated trials. In pounds, both retatrutide groups lost more than twice the average amount reported for the Ozempic group.

However, the comparator was specifically Ozempic 2 mg in adults with type 2 diabetes. The results do not establish that retatrutide outperforms every semaglutide formulation or dose, every approved obesity medicine, or all treatments in people without diabetes.

Ozempic and Wegovy both contain semaglutide, but they are distinct branded treatments with different approved uses and dosing. This trial was not a direct comparison with Wegovy. Likewise, these findings do not establish superiority over tirzepatide; Lilly’s announcement identifies a separate ongoing comparison with tirzepatide.

Why retatrutide is called a triple agonist

Retatrutide targets three hormone receptors: GLP-1, GIP and glucagon. These pathways are involved in appetite, glucose regulation and energy metabolism. Semaglutide targets GLP-1, while tirzepatide targets GLP-1 and GIP.

That three-receptor approach helps explain scientific interest in retatrutide. It does not mean that “three” automatically makes a medicine safer or more suitable for every patient. Those questions require clinical evidence and, ultimately, regulatory review.

Safety findings belong beside the weight-loss figures

Lilly reports gastrointestinal symptoms among the most common adverse events. For retatrutide 9 mg, retatrutide 12 mg and Ozempic 2 mg, respectively, the announcement lists:

• Diarrhea: 28.3%, 32.7% and 26.4%.
• Nausea: 21.2%, 23.8% and 21.3%.
• Vomiting: 10.2%, 15.0% and 13.2%.
• Dysesthesia, or altered sensation: 4.8%, 6.5% and 2.7%.
• Stopping treatment because of adverse events: 4.8%, 7.9% and 2.7%.

The company says most of the listed events were mild to moderate and typically resolved during treatment. Nevertheless, the higher adverse-event discontinuation rate, particularly at 12 mg, is important context. These selected figures are not a complete safety assessment.

Lilly also reports improvements in cholesterol measures, triglycerides and systolic blood pressure. Changes in these risk factors should not be presented as proof that this trial reduced heart attacks, strokes or deaths.

Is retatrutide FDA approved or available for compounding?

No FDA approval is established by this announcement. ABC News reports that retatrutide is not yet FDA approved and that Lilly plans to submit it for approval in early 2027. Review timelines and outcomes remain uncertain.

The FDA’s published guidance on unapproved GLP-1 drugs, marked current as of October 1, 2026, specifically states that retatrutide and cagrilintide cannot be used in compounding under federal law and have not been found safe and effective for any condition.

A clinical-trial announcement is not permission for online sellers to market unapproved retatrutide for personal use. Nor should news about compounding access for other peptides be assumed to change retatrutide’s status. Discuss treatment choices with a licensed clinician rather than buying products advertised as research chemicals or switching medicines on the strength of a headline.

What these findings mean for wellness strips

This trial studied an investigational injection—not oral wellness strips. It does not establish that a Neuvéra product contains the same tested medicine, has equivalent absorption or dosing, or delivers the trial’s weight-loss or diabetes outcomes.

A shared ingredient name or similar marketing language is not evidence of equivalence. A strip, compounded preparation and clinical-trial injection cannot be treated as interchangeable without appropriate product-specific evidence. Product testing alone also does not demonstrate clinical effectiveness.

If you are separately researching strip formats, visit our strip directory and comparison page or explore the Formula Library. The directory provides onward links to Neuvéra for product information and purchasing. Those links are navigation resources, not recommendations to replace prescribed treatment.

Commercial context: Strips Over Needles is a directory and referral site that directs shoppers to Neuvéra. This news explainer does not endorse Neuvéra products as substitutes for retatrutide, Ozempic or any prescription medicine.

What to watch next

Lilly says detailed results will be presented at a future medical meeting and published in a peer-reviewed journal. That means the announcement is an early summary, not the complete peer-reviewed report of this trial.

Useful next milestones include full methods and safety reporting, any regulatory submission and the FDA’s eventual decision. For now, the careful takeaway is that retatrutide produced substantial average weight loss and A1C reductions in the reported diabetes trial, while important questions about full evidence, approval and clinical use remain.

Sources and editorial notes

1. ABC News: New weight loss drug retatrutide provides double the weight loss of Ozempic, Lilly says. Youri Benadjaoud, October 28, 2026. Independent reporting that prompted this explainer.
2. Eli Lilly: Retatrutide head-to-head TRANSCEND-T2D-2 topline results. October 28, 2026. Primary source for efficacy and safety numbers; a manufacturer announcement, not an independent peer-reviewed publication.
3. FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Page marked current as of October 1, 2026 and reviewed for this article on October 28, 2026.

This is an original summary and analysis of the linked sources, not a reproduction of the ABC News article. Findings and regulatory guidance can change. Consult the dated source documents for subsequent developments.